DNDi and Atomwise collaborate to advance drug development using AI for neglected diseases

Geneva, Switzerland and San Francisco, USA – 16 April 2019
Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development
Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and DNDi, a not-for-profit research and development organization working to deliver new treatments for neglected diseases, today announced that promising drug-like compounds have been discovered in a programme to develop first-in-class treatments for Chagas disease. The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards programme.

Chagas disease: the time is now to end 110 years of neglect

Rio de Janeiro – 11 April 2019
The people affected by Chagas disease will claim this 14th of April as World Chagas Day in the hope of increasing global awareness, building on the progress already made against this disease, which has been neglected for more than a century
The International Federation of Associations of People Affected by Chagas disease (FINDECHAGAS) has launched an online petition through the platform change.org in support of the official declaration of April 14th as their World Day. This proposal will be tabled at the 72nd World Health Assembly, to be held in Geneva at the end of May 2019. The particular date has been chosen because on that same day, 110 years ago, the Brazilian doctor Carlos Chagas confirmed the first case of the disease in a child, called Berenice Soares.

GARDP set up as independent legal entity

Geneva, Switzerland – 2 April 2019
Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR
GARDP is now an independent legal entity following a successful three-year incubation, hosted by DNDi. During this time, GARDP has already begun working with partners to develop antibiotics to tackle drug-resistant infections which pose a threat to global health and development, including the achievement of the Sustainable Development Goals.

Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis

London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.

Le fexinidazole, premier traitement entièrement par voie orale contre la maladie du sommeil, approuvé en République Démocratique du Congo

Paris/Genève, 30 Janvier 2019

La République Démocratique du Congo (RDC) a délivré une autorisation de mise sur le marché au fexinidazole pour le traitement de la trypanosomiase humaine africaine (THA) ou maladie du sommeil causée par le parasite Trypanosoma brucei gambiense. Cette approbation ouvre la voie à la distribution du  fexinidazole, cette année, dans les pays où la maladie du sommeil est endémique, sachant qu’une autre soumission réglementaire est également prévue en Ouganda.

Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo

Paris/Geneva – 30 January 2019
Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis, more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC). This approval paves the way for the distribution of fexinidazole in endemic countries this year, with another submission planned in Uganda.

アフリカ睡眠病初の経口治療薬フェキシニダゾールがコンゴ民主共和国において承認を取得

[2019年1月30日 パリ/ジュネーブ]

ガンビア・トリパノソーマ (Trypanosoma brucei gambiense) によるヒト・アフリカ・トリパノソーマ症 (HAT、別名アフリカ睡眠病) の治療薬として、コンゴ民主共和国 (DRC) においてフェキシニダゾールの申請が承認されました。これにより、ウガンダで予定されている申請とともに、今年フェキシニダゾールを流行国において普及させる道が開かれました。